1. |
Chong CR, Sullivan DJ. New uses for old drugs. Nature, 2007, 448(7154): 645-646.
|
2. |
Dimasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ, 2003, 22(2): 151-185.
|
3. |
Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol, 2014, 32(1): 40-51.
|
4. |
盛苗苗, 蒋澄宇. 精确医学为老药新用及联合用药带来新契机. 生命科学, 2015, 27(3): 322-326.
|
5. |
Ekins S, Williams AJ. Finding promiscuous old drugs for new uses. Pharm Res, 2011, 28(8): 1785-1791.
|
6. |
Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat product, 2012, 75(3): 311-335.
|
7. |
Cragg GM, Grothaus PG, Newman DJ. New horizons for old drugs and drug leads. J Nat Prod, 2014, 77(3): 703-723.
|
8. |
Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science, 2009, 325(5937): 161-165.
|
9. |
Sun Y, Liu Y, Chen K. Roles and mechanisms of ginsenoside in cardiovascular diseases: progress and perspectives. Sci China Life Sci, 2016, 59(3): 292-298.
|
10. |
Smith I, Williamson EM, Putnam S, et al. Effects and mechanisms of ginseng and ginsenosides on cognition. Nutr Rev, 2014, 72(5): 319-333.
|
11. |
Geng J, Dong J, Ni H, et al. Ginseng for cognition. Cochrane Database Syst Rev, 2010, (12): CD007769.
|
12. |
Yang Z, Zhao T, Liu H, et al. Ginsenoside Rh2 inhibits hepatocellular carcinoma through β-catenin and autophagy. Sci Rep, 2016, 6: 19383.
|
13. |
Tian L, Shen D, Li X, et al. Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4. Oncotarget, 2016, 7(2): 1619.
|
14. |
Guo M, Liu Y, Shi D. Cardiovascular actions and therapeutic potential of tetramethylpyrazine (active component isolated from rhizoma chuanxiong): roles and mechanisms. Biomed Res Int, 2016, 2016: 2430329.
|
15. |
Hui L, Xue YA, Wei SH, et al. Protective effects of tetramethylpyrazine on cerebrovascular regulations in rats with chronic alcoholic encephalopathy. Biomed Environ Sci, 2015, 28(9): 691-695.
|
16. |
Kong X, Zhong M, Su X, et al. Tetramethylpyrazine promotes migration of neural precursor cells via activating the phosphatidylinositol 3-kinase pathway. Mol Neurobiol, 2016, 53(9): 6526-6539.
|
17. |
Wang C, Wang P, Zeng W, et al. Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway. Bioorg Med Chem Lett, 2016, 26(4): 1287-1291.
|
18. |
Yin J, Zhang H, Ye J. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets, 2008, 8(2): 99-111.
|
19. |
Xia X, Yan J, Shen Y, et al. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One, 2011, 6(2): e16556.
|
20. |
Tillhon M, Ortiz LM, Lombardi P, et al. Berberine: new perspectives for old remedies. Biochem Pharmacol, 2012, 84(10): 1260-1267.
|
21. |
Mahmood K, Zia KM, Zuber M. Recent developments in curcumin and curcumin based polymeric materials for biomedical applications: a review. Int J Biol Macromol, 2015, 81: 877-890.
|
22. |
Seo HJ, Wang SM, Han C, et al. Curcumin as a putative antidepressant. Expert Rev Neurother, 2015, 15(3): 269-280.
|
23. |
Kaufmann FN, Gazal M, Bastos CR, et al. Curcumin in depressive disorders: an overview of potential mechanisms, preclinical and clinical findings. Eur J Pharmacol, 2016, 784: 192-198.
|
24. |
Al-Karawi D, Mamoori A, Alem D, et al. The role of curcumin administration in patients with major depressive disorder: mini meta-analysis of clinical trials. Phytother Res, 2016, 30(2): 175-183.
|
25. |
Ho WE, Peh HY, Chan TK, et al. Artemisinins: pharmacological actions beyond anti-malarial. Pharmacol Ther, 2014, 142(1): 126-139.
|
26. |
Jin O, Zhang H, Gu Z, et al. A pilot study of the therapeutic efficacy and mechanism of artesunate in the MRL/lpr murine model of systemic lupus erythematosus. Cell Mol Immunol, 2009, 6(6): 461.
|
27. |
Li J, Casteels T, Frogne T, et al. Artemisinins target GABAA receptor signaling and impair α cell identity. Cell, 2017, 168(1-2): 86-100, 115.
|
28. |
Liu J, Lee J, Salazar HMA, et al. Treatment of obesity with celastrol. Cell, 2015, 161(5): 999-1011.
|
29. |
信琪琪, 刘玥, 杨琳, 等. 中药银杏制剂与糖尿病治疗: 作用机制与临床应用. 中国中药杂志, 2014, 39(23): 4509-4515.
|
30. |
Zhi Y, Pan JH, Shen WH, et al. Ginkgolide B inhibits human bladder cancer cell migration and invasion through MicroRNA-223-3p. Cell Physiol Biochem, 2016, 39(5): 1787-1794.
|
31. |
Xu K, Wang P, Xu X, et al. An overview on structural modifications of ligustrazine and biological evaluation of its synthetic derivatives. Res Chem Intermediat, 2015, 41(3): 1385-1411.
|
32. |
刘瑞武, 尹大力, 郭积玉. 10 位结构修饰 14β-侧链紫杉醇衍生物的合成及其抗肿瘤活性. 中国药物化学杂志, 2000, 10(1): 18-25.
|
33. |
Li Q, Wang Y, Feng N, et al. Novel polymeric nanoparticles containing Tanshinone IIA for the treatment of hepatoma. J Drug Target, 2008, 16(10): 725-732.
|
34. |
任瑾, 杜倩, 艾凤伟, 等. 药物新剂型与新技术在中药制剂中的应用开发. 中成药, 2015, 37(2): 392-396.
|
35. |
Li S. Farmework and practice of network based studies for Chinese herbal formula. J Chin Integr Med, 2007, 5(5): 489-493.
|
36. |
Hopkins AL. Network pharmacology. Nat Biotechnol, 2007, 25(10): 1110-1111.
|
37. |
Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol, 2008, 4(11): 682-690.
|
38. |
张彦琼, 李梢. 网络药理学与中医药现代研究的若干进展. 中国药理学与毒理学杂志, 2015, 29(6): 883-892.
|
39. |
张永祥, 程肖蕊, 周文霞. 药物重定位—网络药理学的重要应用领域. 中国药理学与毒理学杂志, 2012, 26(6): 779-786.
|
40. |
Yang H, Shen Y, Chen J, et al. Structure-based virtual screening for identification of novel 11β-HSD1 inhibitors. Eur J Med Chem, 2009, 44(3): 1167.
|
41. |
梁英喜, 贺昱甦, 蒋芦荻, 等. 利用重定位策略从中药中发现 L-型钙离子通道作用降压药. 中国中药杂志, 2015, 40(18): 2650-2654.
|
42. |
杨 珍, 张燕玲, 乔延江. ETB 受体拮抗剂三维药效团的构建. 世界科学技术-中医药现代化, 2014, 14(4): 1786-1792.
|
43. |
吴纯伟, 路丽, 梁生旺, 等. 药物靶标预测技术在中药网络药理学中的应用. 中国中药杂志, 2016, 41(3): 377-382.
|
44. |
Liang XJ, Li HY, Li S. A novel network pharmacology approach to analyse traditional: herbal formulae: the liu-wei-di-huang pill as a case study. Mol Bio Syst, 2014, 10(5): 943-1212.
|
45. |
Li HY, Zhao LH, Zhang B, et al. A network pharmacology approach to determine active compounds and action mechanisms of ge-gen-qin-lian decoction for treatment of type 2 diabetes. Evid Based Complement Alternat Med, 2014, 2014: 495840.
|
46. |
Liu HP, Zeng LT, Yang KL, et al. A network pharmacology approach to explore the pharmacological mechanism of xiaoyao powder on anovulatory infertility. Evid Based Complement Alternat Med, 2016, 2016: 2960372.
|
47. |
李翔, 吴磊宏, 范骁辉, 等. 复方丹参方主要活性成分网络药理学研究. 中国中药杂志, 2011, 36(21): 2912-2915.
|
48. |
Nielsen SK, Ursu O, Yang JJ, et al. Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing. Mol Inform, 2011, 30(2-3): 100-111.
|